Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide

Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide

Background: Baseline high circulating tumor DNA (ctDNA) fraction in plasma and androgen receptor (AR) copy number (CN) gain identify mCRPC patients with worse outcomes. This study aimed to assess if ctDNA associates with PSA kinetics. Methods: In this prospective biomarker study, we evaluate ctDNA f...

Full description

Bibliographic Details
Main Authors: Vincenza Conteduca, Chiara Casadei, Emanuela Scarpi, Nicole Brighi, Giuseppe Schepisi, Cristian Lolli, Giorgia Gurioli, Ilaria Toma, Giulia Poti, Alberto Farolfi, Ugo De Giorgi
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Cancers
Subjects:
metastatic castration-resistant prostate cancer
AR copy number
circulating tumor DNA
biomarkers
Online Access:https://www.mdpi.com/2072-6694/14/9/2219

Internet

https://www.mdpi.com/2072-6694/14/9/2219

Similar Items